Success achieved with the first-in-class oral anti-cancer drug, Inobrodib, by CellCentric and Sygnature Discovery.
![Cancer lensatpes med](https://lenstapesmed.com/wp-content/uploads/2022/12/Cancer-lensatpes-med-1024x576.jpg)
An integrated project team at Sygnature Discovery worked collaboratively to design, synthesise, and support the pre-clinical development of Inobrodib, a new, first-in-class oral anti-cancer drug being developed by CellCentric. What are Androgens? Androgens are ‘male hormones’ including testosterone and dihydrotestosterone. They carry out their actions through a receptor called Androgen Receptor (AR), which is expressed […]